Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


857 - Chronic Arsenic Poisoning leading to Skin Malignancy in a Community (383O)


17 Nov 2017




Cancer Prevention;  Skin Cancers


Vipin Goel


Annals of Oncology (2017) 28 (suppl_10): x113-x116. 10.1093/annonc/mdx667


V. Goel

Author affiliations

  • Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, 500034 - Hyderabad/IN


Abstract 857


To elucidate the etiology of skin malignancy in people in the hamlet of Kiradalli, Yadgir District, Karnataka State, India, where many people experienced skin lesions that transformed into malignancy.


A cross-sectional survey of the inhabitants of Kiradalli was performed by trained and supervised paramedics. Skin lesions were documented. Lesions with a high suspicion of malignancy underwent biopsy. Drinking water was analyzed at the Cochin University of Science and Technology for arsenic content. Blood of affected patients was sent for arsenic level estimation and compared with normal levels. The media and social activists were involved to highlight this community health issue to help provide an alternative source of water and to provide rehabilitation.


Forty-six people were found to have skin changes suspicious for arsenic keratosis. Ten cases of epidermal malignancy were noted. A prevalence of 2.38% for epidermal neoplasm and 10.9% for arsenic keratosis was documented. The arsenic level of the water was 0.483 mg/L—much higher than the permitted level. Arsenic in the blood of affected patients was high. Among 10 cases, 9 cases are alive and 1 patient died of cardiac cause.


Arsenic in the drinking water as a cause of skin cancer was established. The primary preventative measure to halt the development of new lesions was to provide safe drinking water for residents. The secondary preventative measure was to improve the prognosis of patients with malignant lesions by early diagnosis and treatment.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.